Sanofi (SNY) news
Recent news
Vir Biotechnology - May receive up to $1.74 bln in additional milestones plus tiered royalties
Vir Biotechnology, Inc. (Nasdaq: VIR) has entered into a global strategic collaboration with Astellas Pharma Inc. to co-develop and co-commercialize VIR-5500, an investigational prostate-specific membrane antigen (PSMA)-targeted T-cell engager (TCE) for the treatment of prostate cancer. Under the…
AInvest Wire · 20h agoSanofi settles EU case over disparagement of vaccine rival
AInvest Wire · 1d agoEU antitrust regulators accept Sanofi's offer to stop disparaging rival flu vaccine, no fine for Sanofi
AInvest Wire · 1d agoNurix 3Q R&D expenses $79.3M, est. $77.1M
Nurix Therapeutics, Inc. (Nasdaq: NRIX) reported research and development (R&D) expenses of $79.3 million for the third quarter of fiscal 2024, exceeding the estimated $77.1 million for the period. The increase in R&D spending reflects the company’s continued investment in its clinical trial…
AInvest Wire · 2d agoNurix 3Q rev. $19.9M est. $24.4M
Nurix Therapeutics, Inc. (Nasdaq: NRIX) reported financial results for the first quarter of fiscal 2026, with revenue coming in below estimates. Revenue for the three months ended February 28, 2026, was $6.3 million, compared to $18.5 million in the same period in 2025. This decline was primarily…
AInvest Wire · 2d agoLight Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.